Corbus Pharmaceuticals (NASDAQ:CRBP) CFO Sells $120,960.00 in Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean Moran sold 12,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $10.08, for a total value of $120,960.00. Following the completion of the transaction, the chief financial officer owned 84,694 shares of the company’s stock, valued at $853,715.52. This trade represents a 12.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Corbus Pharmaceuticals Stock Up 2.6%

CRBP stock opened at $9.76 on Thursday. Corbus Pharmaceuticals Holdings, Inc. has a 52-week low of $7.12 and a 52-week high of $20.56. The stock’s fifty day simple moving average is $8.84 and its 200-day simple moving average is $9.07. The stock has a market capitalization of $182.22 million, a price-to-earnings ratio of -1.58 and a beta of 2.59.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). As a group, analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in Corbus Pharmaceuticals during the 1st quarter worth approximately $573,000. Marshall Wace LLP acquired a new position in Corbus Pharmaceuticals during the second quarter valued at approximately $137,000. Bank of America Corp DE grew its stake in Corbus Pharmaceuticals by 333.6% during the second quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock worth $496,000 after buying an additional 55,314 shares during the period. Vanguard Group Inc. grew its stake in Corbus Pharmaceuticals by 2.1% during the third quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after buying an additional 12,535 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals in the third quarter worth $129,000. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on CRBP. HC Wainwright dropped their price objective on shares of Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Jefferies Financial Group lowered their target price on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Oppenheimer dropped their price target on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. Finally, Mizuho decreased their price target on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating on the stock in a report on Tuesday, June 23rd. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.12.

More Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Director Nishant C. Saxena purchased 2,600 CRBP shares for approximately $25,038 at an average price of $9.63, increasing his direct ownership by 3.45%. Insider buying can signal management confidence in the company’s valuation. SEC insider ownership filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, substantially above recent trading levels. The firm continues to model a return to profitability by 2030, although its estimates were lowered.
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the data showed no short position and no meaningful change, it provides little actionable signal for investors.
• Negative Sentiment: HC Wainwright cut EPS forecasts across 2026-2030, including 2026 to a loss of $6.11 per share from $4.99, 2027 to a loss of $6.83 from $5.66, and 2030 profit to $0.15 from $1.29. The revisions point to weaker near- and long-term earnings expectations despite the Buy rating.
• Negative Sentiment: CFO Sean Moran sold 12,000 shares for approximately $120,960, reducing his holdings by 12.41%. The sale may weigh on sentiment, although insider transactions do not necessarily indicate a change in the company’s outlook. CFO stock sale report
• Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate, reinforcing concerns about continued cash burn and execution risk for its clinical-stage pipeline.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.